DK168767B1 - DNA-sekvens, der koder for et modificeret human-IL-2 protein, hvori 125-cysteinresten er udskiftet med en anden aminosyrerest, ekspressionsvektor indeholdende DNA-sekvensen, værtcelle eller -organisme transformeret med ekspressionsvektoren samt fremgangsmåde til fremstilling af det modificerede protein - Google Patents

DNA-sekvens, der koder for et modificeret human-IL-2 protein, hvori 125-cysteinresten er udskiftet med en anden aminosyrerest, ekspressionsvektor indeholdende DNA-sekvensen, værtcelle eller -organisme transformeret med ekspressionsvektoren samt fremgangsmåde til fremstilling af det modificerede protein Download PDF

Info

Publication number
DK168767B1
DK168767B1 DK481383A DK481383A DK168767B1 DK 168767 B1 DK168767 B1 DK 168767B1 DK 481383 A DK481383 A DK 481383A DK 481383 A DK481383 A DK 481383A DK 168767 B1 DK168767 B1 DK 168767B1
Authority
DK
Denmark
Prior art keywords
protein
expression vector
dna sequence
modified
amino acid
Prior art date
Application number
DK481383A
Other languages
Danish (da)
English (en)
Other versions
DK481383A (da
DK481383D0 (da
Inventor
David F Mark
Leo S Lin
Shi-Da Yu Lu
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27030446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK168767(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cetus Corp filed Critical Cetus Corp
Publication of DK481383D0 publication Critical patent/DK481383D0/da
Publication of DK481383A publication Critical patent/DK481383A/da
Application granted granted Critical
Publication of DK168767B1 publication Critical patent/DK168767B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/141—Interleukin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK481383A 1982-10-19 1983-10-19 DNA-sekvens, der koder for et modificeret human-IL-2 protein, hvori 125-cysteinresten er udskiftet med en anden aminosyrerest, ekspressionsvektor indeholdende DNA-sekvensen, værtcelle eller -organisme transformeret med ekspressionsvektoren samt fremgangsmåde til fremstilling af det modificerede protein DK168767B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43515482A 1982-10-19 1982-10-19
US43515482 1982-10-19
US48616283A 1983-04-15 1983-04-15
US48616283 1983-04-15

Publications (3)

Publication Number Publication Date
DK481383D0 DK481383D0 (da) 1983-10-19
DK481383A DK481383A (da) 1984-04-20
DK168767B1 true DK168767B1 (da) 1994-06-06

Family

ID=27030446

Family Applications (2)

Application Number Title Priority Date Filing Date
DK481383A DK168767B1 (da) 1982-10-19 1983-10-19 DNA-sekvens, der koder for et modificeret human-IL-2 protein, hvori 125-cysteinresten er udskiftet med en anden aminosyrerest, ekspressionsvektor indeholdende DNA-sekvensen, værtcelle eller -organisme transformeret med ekspressionsvektoren samt fremgangsmåde til fremstilling af det modificerede protein
DK105892A DK171681B1 (da) 1982-10-19 1992-08-26 DNA-sekvens, der koder for et modificeret human-beta-interferonprotein (IFN-beta), hvori 17-cysteinresten er udskiftet med en anden aminosyrerest, ekspressionsvektor indeholdende DNA-sekvensen, værtcelle, der er transpormeret med ekspressionsvektorer samt fremgangsmåde til fremstilling af det modificerede protein

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK105892A DK171681B1 (da) 1982-10-19 1992-08-26 DNA-sekvens, der koder for et modificeret human-beta-interferonprotein (IFN-beta), hvori 17-cysteinresten er udskiftet med en anden aminosyrerest, ekspressionsvektor indeholdende DNA-sekvensen, værtcelle, der er transpormeret med ekspressionsvektorer samt fremgangsmåde til fremstilling af det modificerede protein

Country Status (23)

Country Link
EP (4) EP0109748B1 (fr)
JP (2) JPS6128392A (fr)
KR (1) KR910009900B1 (fr)
AT (4) ATE61407T1 (fr)
AU (1) AU563962B2 (fr)
BE (1) BE898016A (fr)
CA (1) CA1340861C (fr)
CH (1) CH669395A5 (fr)
DE (4) DE3380598D1 (fr)
DK (2) DK168767B1 (fr)
ES (4) ES526541A0 (fr)
FI (1) FI82266C (fr)
FR (1) FR2534594B1 (fr)
GB (1) GB2130219B (fr)
GR (1) GR79408B (fr)
IE (1) IE56026B1 (fr)
IL (1) IL69970A (fr)
LU (3) LU88761I2 (fr)
NL (2) NL930119I2 (fr)
NO (1) NO173740C (fr)
NZ (1) NZ205922A (fr)
PH (2) PH20343A (fr)
PT (1) PT77512B (fr)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI82266C (fi) * 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
ZA844082B (en) * 1983-06-01 1985-09-25 Hoffmann La Roche Polypeptides having interferon activity
WO1985000817A1 (fr) * 1983-08-10 1985-02-28 Amgen Expression microbienne de l'interleukine ii
GB8334102D0 (en) * 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
EP0211835B1 (fr) 1984-03-28 1990-01-03 Cetus Corporation Compositions pharmaceutiques d'interleucine-2 produite par voie microbienne
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
ATE48641T1 (de) * 1984-05-08 1989-12-15 Genetics Inst Ein menschlicher t-zellwachstumsfaktor.
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
IL75318A (en) * 1984-05-31 1994-08-26 Genentech Inc Recombinant human memotoxin and methods for its recombinant production
US5683688A (en) * 1984-05-31 1997-11-04 Genentech, Inc. Unglycosylated recombinant human lymphotoxin polypeptides and compositions
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
CA1275954C (fr) 1984-08-31 1990-11-06 Hing Cheug Wong Fragments augmentant l'expression en 3' et methode
IL76360A0 (en) 1984-09-26 1986-01-31 Takeda Chemical Industries Ltd Mutual separation of proteins
WO1986002068A1 (fr) * 1984-09-26 1986-04-10 Takeda Chemical Industries, Ltd. Separation mutuelle de proteines
US4857316A (en) * 1984-10-03 1989-08-15 Syntex (U.S.A.) Inc. Synergistic antiviral composition
US4606917A (en) * 1984-10-03 1986-08-19 Syntex (U.S.A) Inc. Synergistic antiviral composition
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
DK172052B1 (da) * 1984-12-21 1997-09-29 Otsuka Pharma Co Ltd Antitumor-aktivt stof, fremgangsmåde til dets fremstilling, lægemiddel indeholdende stoffet, gen kodende for stoffet, vektor indeholdende genet samt rekombinant mikroorganisme transformet med en sådan vektor
US6107465A (en) * 1984-12-21 2000-08-22 Otsuka Pharmaceutical Co., Ltd. IL-1β and derivatives thereof and drugs
US5342614A (en) * 1984-12-21 1994-08-30 Otsuka Pharmaceutical Co., Ltd. Method of treating arthritus or inflammation with IL-1β or derivatives thereof
DE3500681A1 (de) * 1985-01-11 1986-07-17 Hoechst Ag, 6230 Frankfurt Verfahren zur isolierung und reinigung von lymphokinen
US4863849A (en) * 1985-07-18 1989-09-05 New York Medical College Automatable process for sequencing nucleotide
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US6004548A (en) 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
CA1297003C (fr) * 1985-09-20 1992-03-10 Jack H. Nunberg Composition et methode pour traiter les animaux
US5359035A (en) * 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
US5008374A (en) * 1986-03-14 1991-04-16 Otsuka Pharmaceutical Co., Ltd. IL-1α derivatives and drugs
AU595864B2 (en) * 1986-03-14 1990-04-12 Otsuka Pharmaceutical Co., Ltd. Il-1 alpha derivatives and drugs
ATE72582T1 (de) * 1986-09-05 1992-02-15 Cetus Corp Oxidationsresistente muteine von beta-interferon, deren herstellung und diese muteine enthaltende praeparate.
JP2526965B2 (ja) * 1987-02-24 1996-08-21 武田薬品工業株式会社 ムテイン，ｄｎａおよびその用途
DK175535B1 (da) * 1987-03-04 2004-11-29 Daiichi Suntory Pharma Co Ltd Fremgangsmåde til fremstilling af et fysiologisk aktivt cysteinholdigt peptid
EP0298723A1 (fr) * 1987-07-07 1989-01-11 California Biotechnology, Inc. Facteurs de croissance de fibroblaste recombinants
JP2602968B2 (ja) * 1987-11-04 1997-04-23 カリフォルニア バイオテクノロジー インコーポレイテッド 肺胞の界面活性タンパク類
DE68929273T2 (de) * 1988-08-24 2001-07-05 American Cyanamid Co., Wayne Stabilisierung von Somatotropinen durch Modifikation von Cystein-Resten durch orts-spezifische Mutagenese oder chemische Derivatisierung
US5079230A (en) * 1988-09-12 1992-01-07 Pitman-Moore, Inc. Stable bioactive somatotropins
CA2003886A1 (fr) * 1988-12-16 1990-06-16 Anthony F. Purchio Clonage et expression du facteur de croissance-beta-1 transformateur simien
AU620673B2 (en) * 1989-01-31 1992-02-20 Pharmacia & Upjohn Company Somatotropin analogs
DK0383599T3 (da) * 1989-02-17 1996-08-05 Merck & Co Inc Protein-anticancermiddel
US5621078A (en) * 1989-03-22 1997-04-15 Merck & Co., Inc. Modified pseudomonas exotoxin PE40
AU5355790A (en) * 1989-04-19 1990-11-16 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
US6207798B1 (en) 1989-08-03 2001-03-27 Merck & Co., Inc. Modified PE40 toxin fusion proteins
US5173297A (en) * 1991-07-01 1992-12-22 Quest International Flavors & Food Ingredients Company Division Of Indopco, Inc. Bacteriocin from lactococcus lactis subspecies lactis
IL98528A0 (en) * 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
FR2671554A1 (fr) * 1991-01-11 1992-07-17 Clonatec Sa Peptides synthetiques derivant de l'antigene hbc du virus de l'hepatite b, leurs applications a la detection d'une infection par ce virus et a la vaccination contre l'hepatite b.
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
US5814485A (en) * 1995-06-06 1998-09-29 Chiron Corporation Production of interferon-β (IFN-β) in E. coli
DE19544167A1 (de) * 1995-11-17 1997-05-22 Schering Ag Verwendung von Interferon-ß zur Behandlung von Bronchialkarzinom bei Bestrahlungstherapie
AU6399996A (en) * 1996-06-19 1998-01-07 Chiron Corporation Bacterial production of interferon-beta using low levels of sodium and potassium ions
CN1100875C (zh) * 1998-03-06 2003-02-05 上海华晨生物技术研究所 新型重组人白细胞介素2的制备方法及其表达载体和工程菌
EP1276756A4 (fr) 2000-04-12 2004-06-09 Human Genome Sciences Inc Proteines de fusion d'albumine
EP1935431A3 (fr) 2000-05-15 2008-08-13 Health Research, Inc. Traitements anti-cancéreux utilisant une combinaison d'anticorps contre le HER2 et l'interleukine-2
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
CA2463935A1 (fr) * 2001-09-18 2003-03-27 Chiron Corporation Methodes de traitement de la sclerose en plaques
KR100511749B1 (ko) * 2001-11-06 2005-09-02 선바이오(주) 변형된 인터페론-베타, 및 이의 화학적으로 변형된 배합체
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
CA2496317C (fr) 2002-09-11 2014-02-18 Fresenius Kabi Deutschland Gmbh Procede de production de derives d'amidon hydroxyalkyle
AU2003273413A1 (en) 2002-10-08 2004-05-04 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
WO2005014655A2 (fr) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugues d'amidon d'hydroxyalkyle et de proteine
PT1682180E (pt) 2003-11-04 2010-02-10 Novartis Vaccines & Diagnostic Anticorpos monoclonais antagonistas anti-cd40 e métodos para a sua utilização
KR20070003934A (ko) * 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
EP2336192A1 (fr) 2004-03-11 2011-06-22 Fresenius Kabi Deutschland GmbH Conjugues d'amidon hydroxyalkyle et d'une protein, preparer par amination réductive
EP1786917A4 (fr) * 2004-07-26 2008-05-28 Enzon Pharmaceuticals Inc Gene optimise pour exprimer l'interferon beta
GB0523282D0 (en) 2005-11-15 2005-12-21 Isis Innovation Methods using pores
GB2453377A (en) 2007-10-05 2009-04-08 Isis Innovation Transmembrane protein pores and molecular adapters therefore.
EP2070950A1 (fr) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Dérivés hydroxyalkylés de l'amidon et leur procédé de préparation
ATE548052T1 (de) 2008-01-17 2012-03-15 Philogen Spa Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler
AU2009269792A1 (en) 2008-07-07 2010-01-14 Oxford Nanopore Technologies Limited Base-detecting pore
US20110229877A1 (en) 2008-07-07 2011-09-22 Oxford Nanopore Technologies Limited Enzyme-pore constructs
US9077937B2 (en) * 2008-11-06 2015-07-07 Alcatel Lucent Method and apparatus for fast channel change
GB0820927D0 (en) 2008-11-14 2008-12-24 Isis Innovation Method
CA2750879C (fr) 2009-01-30 2018-05-22 Oxford Nanopore Technologies Limited Adaptateurs pour des constructions d'acide nucleique dans le sequencage de sequences transmembranaires
EP2391639A1 (fr) 2009-01-30 2011-12-07 Oxford Nanopore Technologies Limited Enzyme mutante
GB0905140D0 (en) 2009-03-25 2009-05-06 Isis Innovation Method
WO2012107778A2 (fr) 2011-02-11 2012-08-16 Oxford Nanopore Technologies Limited Pores mutants
KR102220006B1 (ko) 2011-03-11 2021-02-24 아시스땅스 퍼블리끄-오삐또 드 빠리 자가면역 - 관련 또는 염증성 장애를 치료하기 위한 저용량 ｉｌ­２ 의 용도
BR112014001699A2 (pt) 2011-07-25 2017-06-13 Oxford Nanopore Tech Ltd método para sequenciar de um polinucleotídeo alvo de filamento duplo, kit, métodos para preparar um polinucleotídeo alvo de filamento duplo para sequenciamento e para sequenciar um polinucleotídeo alvo de filamento duplo, e, aparelho
GB201119244D0 (en) 2011-11-08 2011-12-21 British American Tobacco Co Smoking article
CA2869546C (fr) 2012-04-10 2020-07-21 Oxford Nanopore Technologies Limited Pores formes de lysenine mutante
US11155860B2 (en) 2012-07-19 2021-10-26 Oxford Nanopore Technologies Ltd. SSB method
US10221450B2 (en) 2013-03-08 2019-03-05 Oxford Nanopore Technologies Ltd. Enzyme stalling method
GB201314695D0 (en) 2013-08-16 2013-10-02 Oxford Nanopore Tech Ltd Method
GB201313477D0 (en) 2013-07-29 2013-09-11 Univ Leuven Kath Nanopore biosensors for detection of proteins and nucleic acids
EP3013355B1 (fr) 2013-06-25 2019-08-07 ICM - Institut du Cerveau et da la Moelle Epinière Il-2 pour utilisation dans le traitement de la maladie d'alzheimer et de troubles associes
GB201403096D0 (en) 2014-02-21 2014-04-09 Oxford Nanopore Tech Ltd Sample preparation method
EP2918285A1 (fr) 2014-03-11 2015-09-16 Université Pierre et Marie Curie (Paris 6) Interleukin-2 pour traiter une allergie alimentaire
WO2015166275A1 (fr) 2014-05-02 2015-11-05 Oxford Nanopore Technologies Limited Pores mutants
EP3224274B1 (fr) 2014-09-01 2024-02-14 Vib Vzw Pores de csgg mutants
WO2016055778A1 (fr) 2014-10-07 2016-04-14 Oxford Nanopore Technologies Limited Pores mutants
GB201418159D0 (en) 2014-10-14 2014-11-26 Oxford Nanopore Tech Ltd Method
WO2016172445A2 (fr) * 2015-04-24 2016-10-27 The University Of Florida Research Foundation, Inc. Procédés permettant d'identifier des peptides aléatoires biologiquement actifs dans des plantes et des bibliothèques de plantes exprimant des peptides aléatoires biologiquement actifs candidats
US10876109B2 (en) 2015-04-24 2020-12-29 University Of Florida Research Foundation, Inc. Methods of identifying biologically active random peptides in prokaryotic cells and libraries of prokaryotic cells expressing candidate biologically active random peptides
US10801023B2 (en) * 2015-04-24 2020-10-13 University Of Florida Research Foundation, Inc. Methods of identifying biologically active random peptides in plants and libraries of plants expressing candidate biologically active random peptides
CA3001429C (fr) 2015-10-22 2023-07-11 Iltoo Pharma Compositions pharmaceutiques d'il-2
GB201609220D0 (en) 2016-05-25 2016-07-06 Oxford Nanopore Tech Ltd Method
JP7206190B2 (ja) 2016-06-22 2023-01-17 ダヴィド・クラッツマン 遺伝的に修飾されたｔリンパ球
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
MX2019013517A (es) 2017-05-24 2020-08-17 Pandion Operations Inc Inmunotolerancia dirigida.
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
EP3752178A1 (fr) 2018-02-16 2020-12-23 Iltoo Pharma Utilisation de l'interleukine 2 pour traiter le syndrome de sjögren
GB201807793D0 (en) 2018-05-14 2018-06-27 Oxford Nanopore Tech Ltd Method
EP3806888B1 (fr) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Constructions régulatrices dérivées de pde5 et procédés d'utilisation en immunothérapie
WO2020007937A1 (fr) 2018-07-03 2020-01-09 Iltoo Pharma Utilisation de l'interleukine-2 pour le traitement de la sclérose systémique
WO2020035482A1 (fr) 2018-08-13 2020-02-20 Iltoo Pharma Combinaison d'interleukine 2 et d'un inhibiteur de l'interleukine 1, conjugués et utilisations thérapeutiques de celle-ci
EP3880838A4 (fr) 2018-11-15 2022-11-02 The Board of Trustees of the Leland Stanford Junior University Compositions et méthodes de pronostic et de classification pour la prééclampsie
TW202110885A (zh) 2019-05-20 2021-03-16 美商潘迪恩治療公司 靶向ＭＡｄＣＡＭ之免疫耐受性
CN115190885A (zh) 2019-12-12 2022-10-14 艾尔图制药公司 白细胞介素2嵌合构建体
EP4107187A4 (fr) 2020-02-21 2024-07-03 Pandion Operations Inc Immunotolérance ciblée sur un tissu avec un effecteur cd39
TW202146041A (zh) 2020-03-06 2021-12-16 尼姆大學醫學中心 用於肌肉萎縮性脊髓側索硬化症之治療的低劑量人類介白素-2
AU2021264372A1 (en) * 2020-04-29 2022-12-15 Abion Inc. Human interferon-beta variant with double mutation and method for improving stability of human interferon-beta variant
CN116075523A (zh) * 2020-04-29 2023-05-05 基因制药株式会社 具有融合的干扰素-β突变蛋白和抗体的重组蛋白以及包含其的药物组合物
IL311883A (en) 2021-10-06 2024-06-01 Assist Publique H?Pitaux De Paris Interleukin 2 chimeric constructs with targeted specificity for inflammatory tissues
WO2024056154A1 (fr) 2022-09-12 2024-03-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukine-2 pour le traitement des troubles du spectre autistique
WO2024121173A1 (fr) 2022-12-05 2024-06-13 Centre Hospitalier Universitaire De Nimes Interleukine-2 humaine à faible dose pour traitement de la sclérose latérale amyotrophique dans un sous-groupe de patients

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5359688A (en) * 1976-11-11 1978-05-29 Tanpakushitsu Kenkiyuu Shiyour Production of novel polypeptide
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ATE56471T1 (de) * 1980-04-03 1990-09-15 Biogen Inc Dns-sequenzen, rekombinante dns-molekuele und verfahren zur herstellung von dem menschlichen fibroblast-interferon.
JPS58110548A (ja) * 1981-12-24 1983-07-01 Asahi Chem Ind Co Ltd 新規な生理活性ペプチド
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
FI82266C (fi) * 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
ZA844082B (en) * 1983-06-01 1985-09-25 Hoffmann La Roche Polypeptides having interferon activity
WO1985000817A1 (fr) * 1983-08-10 1985-02-28 Amgen Expression microbienne de l'interleukine ii
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins

Also Published As

Publication number Publication date
EP0234599B1 (fr) 1992-03-11
DE3376271D1 (en) 1988-05-19
ES8506801A1 (es) 1985-08-01
LU88357I2 (fr) 1994-05-04
AU563962B2 (en) 1987-07-30
JPH0568480B2 (fr) 1993-09-29
EP0192811B1 (fr) 1991-03-06
GR79408B (fr) 1984-10-22
IE56026B1 (en) 1991-03-27
GB2130219B (en) 1986-01-29
ATE46539T1 (de) 1989-10-15
LU88761I2 (fr) 1996-11-05
FR2534594B1 (fr) 1987-06-19
NL930119I2 (nl) 1995-01-16
KR840006369A (ko) 1984-11-29
FI82266B (fi) 1990-10-31
EP0109748A1 (fr) 1984-05-30
KR910009900B1 (ko) 1991-12-03
NZ205922A (en) 1987-11-27
FI82266C (fi) 1991-02-11
ATE61407T1 (de) 1991-03-15
ES8505717A1 (es) 1985-04-01
DK171681B1 (da) 1997-03-10
EP0109748B1 (fr) 1988-04-13
IE832380L (en) 1984-04-19
NO173740C (no) 1994-01-26
EP0218825A1 (fr) 1987-04-22
LU90413I2 (fr) 1999-09-07
PT77512B (en) 1987-11-24
FI833681A (fi) 1984-04-20
GB8327490D0 (en) 1983-11-16
ES542829A0 (es) 1986-06-01
ATE33503T1 (de) 1988-04-15
NO173740B (no) 1993-10-18
PH23702A (en) 1989-09-27
GB2130219A (en) 1984-05-31
DE3382528D1 (de) 1992-04-16
DE3382197D1 (de) 1991-04-11
FR2534594A1 (fr) 1984-04-20
NL960013I2 (nl) 1997-03-03
ATE73493T1 (de) 1992-03-15
JPS6420096A (en) 1989-01-24
FI833681A0 (fi) 1983-10-10
DK481383A (da) 1984-04-20
BE898016A (fr) 1984-02-15
DK105892A (da) 1992-08-26
ES533054A0 (es) 1985-08-01
EP0192811A1 (fr) 1986-09-03
ES533053A0 (es) 1985-06-16
EP0234599A1 (fr) 1987-09-02
DK481383D0 (da) 1983-10-19
DE3380598D1 (en) 1989-10-26
PH20343A (en) 1986-12-04
EP0218825B1 (fr) 1989-09-20
ES8506089A1 (es) 1985-06-16
CA1340861C (fr) 1999-12-28
PT77512A (en) 1983-11-01
AU2008683A (en) 1984-05-03
DK105892D0 (da) 1992-08-26
IL69970A (en) 1991-05-12
IL69970A0 (en) 1984-01-31
NL930119I1 (nl) 1993-11-01
NO833793L (no) 1984-04-24
ES526541A0 (es) 1985-04-01
ES8608043A1 (es) 1986-06-01
NL960013I1 (nl) 1996-10-01
JPS6128392A (ja) 1986-02-08
CH669395A5 (fr) 1989-03-15

Similar Documents

Publication Publication Date Title
DK168767B1 (da) DNA-sekvens, der koder for et modificeret human-IL-2 protein, hvori 125-cysteinresten er udskiftet med en anden aminosyrerest, ekspressionsvektor indeholdende DNA-sekvensen, værtcelle eller -organisme transformeret med ekspressionsvektoren samt fremgangsmåde til fremstilling af det modificerede protein
DK172276B1 (da) Rekombinant derivat af human tumornekrosefaktor (hTNF), strukturelt gen, som koder for det rekombinante derivat, ekspressionsvektor, værtsceller, transformeret E. coli, fremgangsmåder til fremstilling af det rekombinante derivat og det strukturelle gen, oligonukleotid til brug ved fremstilling af genet, terapeutiske sammensætninger og formuleringer
Wang et al. Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues
US5608036A (en) Enhanced secretion of polypeptides
SE465223B (sv) Moget rekombinant-humanleukocytinterferon och foerfarande foer dess framstaellning
US6268180B1 (en) Recombinant human recombinant human interleukin-1α
EP0212914A2 (fr) Amplification de l'expression de produits d'ADN recombinants
JP2533470B2 (ja) 豚成長ホルモンを生産するためのｄｎａ配列，組換ｄｎａ分子および生産方法
US4762914A (en) Truncated protein of interleukin-1
EP0592566B1 (fr) Muteines d'il-6 depourvues de cysteine
US5077219A (en) Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
EP0370052A1 (fr) Facteur stimulant la croissance des colonies de granulocytes-macrophages humains et ses muteines
EP0194006B1 (fr) Polypeptides analogues d'interféron, procédé pour les préparer et compositions pharmaceutiques les contenant
US5106735A (en) Cloning of a dna sequence encoding a sarcophaga peregrina antibacterial polypeptide precursor
KR0133252B1 (ko) 내열성의 알파-1-안티트립신 뮤테인
US5017486A (en) Cloning of DNA encoding antibacterial polypeptide precursor
JPH02195888A (ja) ヒトインターロイキン２活性を有するポリペプチドをコードする遺伝子を含有する組換えｄｎａ体および該組換えｄｎａ体により形質転換された原核生物細胞
EP0267795A2 (fr) Mutéines de l'interleukine-2 de la souris
EP0190163A1 (fr) Hormone de croissance
AU2131688A (en) Human granulocyte-macrophage colony stimulating factor and muteins thereof
NO306951B1 (no) DNA-sekvens som koder for et modifisert human-IFM-(beta) samt fremgangsmåte for fremstilling derav
KR20020003917A (ko) 꼬리 단백질과 인간 인터루킨-16의 융합 단백질, 이 융합단백질을 코딩하는 유전자, 이 유전자를 포함하는 발현벡터, 이 벡터로 형질전환된 대장균 및 이 대장균을이용한 인간 인터루킨-16의 생산 방법
NO863976L (no) Cystein-beroevede muteiner av biologisk aktive human tumornekrosefaktorproteiner.
JPH0646866A (ja) 耐熱性カルボキシペプチダーゼをコードする遺伝子及びそれを用いた耐熱性カルボキシペプチダーゼの生産方法

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
CTFF Application for supplementary protection certificate (spc) filed

Free format text: CA 1994 00012, 941205

CTFG Supplementary protection certificate (spc) issued

Free format text: CA 1994 00012, 941205, EXPIRES: 20040703

PUP Patent expired